Open AccessAssociation of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection
Author(s) -
Jóice Teixeira de Bitencorte,
Tássia Flores Rech,
Vagner Ricardo Lunge,
Deivid Cruz dos Santos,
Mário Reis ÁlvaresdaSilva,
Dániel Simon
Publication year - 2021
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v13.i1.109
Subject(s) - medicine , hepatocellular carcinoma , interferon , chronic hepatitis , gastroenterology , hepatitis c , alpha interferon , hepatitis , oncology , immunology , virus
Hepatitis C virus (HCV) infection is a public health concern worldwide. Several factors, including genetic polymorphisms, may be evolved in the progression of HCV infection to liver diseases. Interferon lambdas (IFNLs) modulate the immune response during viral infections. IFNLs induce antiviral activity, interfering in the viral replication by promoting the expression of several genes that regulate immunological functions. The interferon lambda-4 ( IFNL4 ) rs12979860 polymorphism, which is characterized by a C to T transition in intron 1, is associated with spontaneous and treatment-induced clearance of HCV infection and may play a role in the development of HCV-associated liver diseases, including hepatocellular carcinoma (HCC).